消结安联合米非司酮治疗子宫肌瘤的临床效果分析  

Clinical efficacy of utilization of Xiaojiean and mifepristone in treatment of uterine fibroid

作　　者：李红梅 

机构地区：[1]江西省婺源县中医院,江西婺源333200

出　　处：《中国当代医药》2013年第25期69-69,71,共2页China Modern Medicine

摘　　要：目的观察消结安联合米非司酮治疗子宫肌瘤的临床效果。方法选取2012年2月～2012年7月在本院就诊的60例子宫肌瘤患者,随机分为观察组和对照组,每组30例。观察组采用消结安联合米非司酮治疗;对照组仅给予米非司酮治疗,对比两组治疗后瘤体大小及疗效。结果观察组治疗后有效率明显要高于对照组,差异有统计学意义(P<0.05);治疗后观察组最大肌瘤体积明显小于对照组,差异有统计学意义(P<0.05)。结论消结安联合米非司酮治疗子宫肌瘤的效果显著,可作为临床首选的治疗方案之一。Objective To evaluate the clinical efficacy of utilization of xiaojiean and mifepristone on the treatment of uterine fibroid.Methods Sixty patients with uterine fibroid who admitted in Wuyuan hospital of traditional Chinese medicine from February 2012 to July 2012 were randomly divided into the intervention group and the control group, with 30 patients in each group respectively. The intervention group received combined utilization of Xiaojiean and mifepristone while the control group received mifepristone alone, Before and after the intervention, the size of uterine fibroid and the therapeutic effect of two groups were observed.Results The effective rate of intervention group was better than control group,and the differences were statistically significant （P〈0.05）; the degree of tumor size decreased significantly higher than control group （P〈0.05）.Conclusion Clinical efficacy of combined utilization of Xiaojiean and mifepristone on the treatment of uterine fibroid is obvious, and the combination utilization can be one of the preferred clinical therapy.

关 键 词：消结安 米非司酮 子宫肌瘤 

分 类 号：R737.33[医药卫生—肿瘤]